Cefiderocol against Multi-Drug and Extensively Drug-Resistant Escherichia coli: An In Vitro Study in Poland

Cefiderocol (CFDC) is a novel, broad-spectrum siderophore cephalosporin with potential activity against multi-drug (MDR) and extensively drug-resistant (XDR) Enterobacterales, including carbapenem-resistant strains. We assessed the in vitro susceptibility to CFDC of MDR, and XDR E. coli isolates derived from clinical samples of hospitalized patients. Disk diffusion (DD) and MIC (minimum inhibitory concentration) test strip (MTS) methods were used. The results were interpreted based on EUCAST (version 12.0 2022) recommendations. Among all E. coli isolates, 98 (94.2%) and 99 (95.2%) were susceptible to CFDC when the DD and MTS methods were used, respectively (MIC range: <0.016-4 mu g/mL, MIC50: 0.19 mu g/mL, MIC90: 0.75 mu g/mL). With the DD and MTS methods, all (MIC range: 0.016-2 mu g/mL, MIC50: 0.19 mu g/mL, MIC90: 0.75 mu g/mL) but three (96.6%) ESBL-positive isolates were susceptible to CFDC. Out of all the metallo-beta-lactamase-positive E. coli isolates (MIC range: 0.016-4 mu g/mL, MIC50: 0.5 mu g/mL, MIC90: 1.5 mu g/mL), 16.7% were resistant to CFDC with the DD method, while 11.1% were resistant to CFDC when the MTS method was used. CFDC is a novel therapeutic option against MDR and XDR E. coli isolates and is promising in the treatment of carbapenem-resistant E. coli strains, also for those carrying Verona integron-encoded metallo-beta-lactamases, when new beta-lactam-beta-lactamase inhibitors cannot be used.

Automated summary

Cefiderocol is a novel siderophore cephalosporin that shows potential activity against multi-drug resistant and extensively drug-resistant Enterobacterales. The study evaluated its in vitro susceptibility against clinical isolates of MDR and XDR E. coli, and found that Cefiderocol exhibited high susceptibility, making it a promising therapeutic option for the treatment of carbapenem-resistant E. coli strains.